Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","amount":"$13.7 million","upfrontCash":"Undisclosed","newsHeadline":"Arthex Biotech Selected for EIC Accelerator Award of up to 14 Million Euros","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arthex Announces Regulatory Milestones Met in Its Program to Develop ATX-01 in Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","amount":"$46.4 million","upfrontCash":"Undisclosed","newsHeadline":"ARTHEx Biotech Announces Closing of \u20ac42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR\u2122 Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by ARTHEx Biotech

    Menu

    ARTHEx Biotech

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ARTHEx Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

              Details:

              ATX-01, an antimiR designed to target microRNA 23b (miR-23b), is the first microRNA therapeutic which is being evaluated for the treatment of Myotonic Dystrophy Type 1.

              Lead Product(s): ATX-01

              Therapeutic Area: Genetic Disease Product Name: ATX-01

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 28, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARTHEx Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)

              Details:

              The Series B proceeds will be used to advance company's lead compound, ATX-01 (amitriptyline hydrochloride), an antimiR designed to target microRNA 23b (miR-23b), to a Phase I/IIa clinical trial for the treatment of Myotonic Dystrophy Type 1 (DM1).

              Lead Product(s): ATX-01

              Therapeutic Area: Neurology Product Name: ATX-01

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Columbus Venture Partners

              Deal Size: $46.4 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing May 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARTHEx Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Arthex Announces Regulatory Milestones Met in Its Program to Develop ATX-01 in Myotonic Dystrophy Type 1

              Details:

              ATX-01 is an investigational drug compound designed to address myotonic dystrophy, a rare progressive muscle wasting disease, by targeting a microRNA involved in the disease pathogenesis.

              Lead Product(s): ATX-01

              Therapeutic Area: Genetic Disease Product Name: ATX-01

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ARTHEx Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Arthex Biotech Selected for EIC Accelerator Award of up to 14 Million Euros

              Details:

              Proceeds will be used to fund the FIGHT-DM 1 project to initiate clinical trial of Arthex' lead candidate, ATX-01, in DM1 in 2023.

              Lead Product(s): ATX-01

              Therapeutic Area: Genetic Disease Product Name: ATX-01

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: EIC Accelerator

              Deal Size: $13.7 million Upfront Cash: Undisclosed

              Deal Type: Funding October 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY